Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Silberstein

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Cephalalgia : an International Journal of Headache|October 11, 2013
Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized studyStephen Silberstein, Susan A McDonald, Jerome Goldstein, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialHong Sun, David W Dodick, Stephen Silberstein, et al.
Neurology|August 25, 2017
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J Goadsby, et al.
Headache|September 2, 2009
Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measuresStephen Silberstein, Richard Lipton, David Dodick, et al.
Journal of Neurointerventional Surgery|November 8, 2023
Refractory migraine: a cerebrovascular disease?David Fiorella, Adam S Arthur, Hsiangkuo Yuan, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind studyRichard B Lipton, Stewart J Tepper, Uwe Reuter, et al.
Headache|August 9, 2008
Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramateStephen Silberstein, Hans-Christoph Diener, Richard Lipton, et al.
Cephalalgia : an International Journal of Headache|November 12, 2019
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensionsMessoud Ashina, David Kudrow, Uwe Reuter, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Cephalalgia : an International Journal of Headache|October 11, 2013
Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: a randomized studyStephen Silberstein, Susan A McDonald, Jerome Goldstein, et al.
The Lancet. Neurology|February 17, 2016
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trialHong Sun, David W Dodick, Stephen Silberstein, et al.
Neurology|August 25, 2017
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J Goadsby, et al.
Headache|September 2, 2009
Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measuresStephen Silberstein, Richard Lipton, David Dodick, et al.
Journal of Neurointerventional Surgery|November 8, 2023
Refractory migraine: a cerebrovascular disease?David Fiorella, Adam S Arthur, Hsiangkuo Yuan, et al.
European Journal of Neurology|January 5, 2021
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trialMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Cephalalgia : an International Journal of Headache|June 1, 2019
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraineMessoud Ashina, Peter J Goadsby, Uwe Reuter, et al.
Neurology|April 19, 2019
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind studyRichard B Lipton, Stewart J Tepper, Uwe Reuter, et al.
Headache|August 9, 2008
Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramateStephen Silberstein, Hans-Christoph Diener, Richard Lipton, et al.
Cephalalgia : an International Journal of Headache|November 12, 2019
Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensionsMessoud Ashina, David Kudrow, Uwe Reuter, et al.
Pageof 9